This Viewpoint describes measures needed for an effective NIH policy in which a single IRB would work with multiple local IRBs to ensure protection of participants in multisite trials.
This study describes characteristics of phase 1 trials, frequency of harms, and communication between investigators and research ethics committees about adverse events to characterize the safety and improve the regulatory review of UK phase 1 trials.
This Viewpoint proposes that institutional review boards play a larger role in ensuring timely public reporting of clinical trial results, with the goals of promoting medical innovation, reducing publication bias, and maximizing the value of clinical trials.
This Viewpoint discusses use of digital multimedia as a strategy to enhance study participants’ understanding of research information.
This Viewpoint discusses the challenges of building research ethics capacity in low- and middle-income countries, reviewing the developments since 2000 and the vision for future research ethics education.
You currently have no searches saved.